Skip to main content
OpenTrials
Completed

NCT Number: NCT02683993

Utilizing Holmium Laser for FURS Renal Stone Lithotripsy Comparing Stone Breaking vs. Stone Dusting Settings

Twenty (20) subjects presenting with a renal stone and candidates for FURS (flexible ureteroscopic renal surgery) will undergo a single FURS procedure for a kidney stone as part of the study, using the study device. These subjects will be randomized into stone breaking treatment or stone dusting.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

New York Methodist Hospital

New York, 11215, United States

About this study

This is a randomized, two-arm, prospective, single center study. Subjects will undergo a single flexible ureteroscopic renal surgery (FURS) procedure for a kidney stone as part of this study, using the study device, and will be treated as randomized to either stone breaking treatment or stone dusting treatment. Follow up visits are scheduled for the day of release from the hospital and at 1 month post procedure. Additional treatment sessions, if required, will be at the discretion of the investigator, as part of the site standard of practice. Additional treatment sessions will not be included in this study.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Subject will be older than 18 years of age
  • Subject was diagnosed with renal calculi meeting the following criteria:
  • Largest stone measures no more than 2cm on a single diameter and is no less than 0.8cm as defined by X-ray or CT.
  • Accumulative stone burden (addition of all stone diameters) is no more than 2.5cm.
  • Subject is a candidate for FURS procedure
  • Subject is willing and has signed the Informed Consent Form

Exclusion criteria

  • Subject has undergone a previous treatment for stones in the same kidney
  • Subject requires another, concomitant procedure, other than FURS, to be performed during this treatment session.
  • Female subject is pregnant
  • Concomitant anticoagulant medication that cannot be suspended during surgery

Treatment and study plan

Lumenis Pulse 120H holmium laser system and 200 DFL ball tip fiber

Device

The Lumenis Pulse P120H will be utilized in high and low frequencies according to subjects group allocation.

Primary outcomes

  1. Stone Clearance

    Time frame: Stone clearance based on 1 month follow-up imaging data

    stone clearance will be confirmed by CT or X-Ray at 1 month follow up.

  2. Post-procedure Catheterization

    Time frame: Post-procedure through hospital discharge; typically discharge occurs on the same day or 1 day post procedure

    Post-procedure catheterization by group

  3. Procedure Time

    Time frame: during the procedure

    Duration (in minutes) of the procedure as an indicator for treatment efficiency.

  4. Usage of Alternative Stone Extracting Devices

    Time frame: as measured during the procedure

    The need of the surgeon to use baskets, forceps or saline flushing to achieve complete stone clearance. This outcome can influence both procedure time and further complication.

  5. Hospital Stay

    Time frame: Procedure through hospital discharge

    Hospital duration was measured to evaluate treatment efficiency

Secondary outcomes

  1. Number of Participants With Intraoperative Complications

    Time frame: Intraoperative

    Number of participants with complications that occur during the procedure.

  2. Visibility During Procedure

    Time frame: Intraprocedural

    Visibility during procedure by group, rating categories: Poor, Fair, Good, Very Good or Excellent

  3. Number of Participants With Occurrence of Retropulsion

    Time frame: Intraoperative

    Occurrence of retropulsion by group

  4. Ability to Reach Stone Fragments

    Time frame: Intraoperative

    Performance rating of ability to reach stone fragments by group

  5. Damage to Scope or Fiber

    Time frame: Intraoperative

    Damage to scope or fiber by group

  6. Fiber Transmission

    Time frame: Intraoperative

    Fiber transmission (preserving energy transmission during lasing) by group

Sponsors and collaborators

Lead sponsor

Boston Scientific Corporation

Industry

Collaborators

  • Lumenis Be Ltd.

Registry information

Important dates

Study start
2016
Primary completion
2017
Study completion
2017
First posted
Feb 17, 2016
Registry last updated
Jan 14, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.